Join our daily newsletter At The Bell to receive exclusive market insights
- Shares in Epsilon Healthcare (EPN) are soaring today after its subsidiary secures a renewal for its medicinal cannabis permit
- Through THC Pharma, the company was also granted increased manufacturing quantities by the Office of Drug Control (ODC)
- The permit will allow Epsilon to keep up with the growing demand from its clients
- The company says the increase in manufacturing quantities is a testimony to its commitment to excellence
- Shares in EPN are up 25 per cent and trading at 2 cents at 1:40 pm AEST
Shares in Epsilon Healthcare (EPN) were soaring today after securing its subsidiary a renewal for its medicinal cannabis permit.
Epsilon’s subsidiary, THC Pharma, was also granted increased manufacturing quantities by the Office of Drug Control (ODC) to keep up with the growing demand from its clients.
Epsilon expressed that the increase in manufacturing quantities was testimony to its commitment to excellence.
The company also said it demonstrated its ability to adapt to the changing needs of the industry.
Epsilon reiterated that as the brand continues to grow, it remains committed to delivering to its clients and patients the highest-quality medicines possible and the “exceptional” level of care they’ve come to expect.
EPN owns a number of medicinal cannabis assets including the largest good manufacturing practice (GMP) cannabis manufacturing facility in the southern hemisphere.
Shares in EPN were up 25 per cent and trading at 2 cents at 1:40 pm AEST.
